CAJ | 학술논문

目的：评价热疗联合周剂量多西紫杉醇化疗治疗老年晚期非小细胞肺癌（NSCLC ）的疗效和安全性。方法选取2012年1月至2014年1月新疆医科大学附属中医医院65岁或以上的老年NSCLC住院患者102例，分为治疗组与对照组，各51例；治疗组给予热疗联合周剂量多西紫杉醇单药化疗，对照组给予周剂量多西紫杉醇单药化疗，2周期后进行疗效评价。结果本研究纳入病例102例，可评价病例96例，治疗组患者的疾病控制率明显高于对照组，比较差异有统计学意义（ P＜0．05）；仅治疗组治疗后血清癌胚抗原及细胞角蛋白19片段抗原水平显著降低，与治疗前比较差异有统计学意义（P＜0．05）；两组消化道不良反应、骨髓抑制方面差异无统计学意义（P＞0．05）。结论热疗联合周剂量多西紫杉醇单药化疗疗效较好，不良反应轻，可作为老年肺癌治疗方案之一，同时监测肺癌相关肿瘤标志物动态变化以判断疗效及预后。
목적：평개열료연합주제량다서자삼순화료치료노년만기비소세포폐암（NSCLC ）적료효화안전성。방법선취2012년1월지2014년1월신강의과대학부속중의의원65세혹이상적노년NSCLC주원환자102례，분위치료조여대조조，각51례；치료조급여열료연합주제량다서자삼순단약화료，대조조급여주제량다서자삼순단약화료，2주기후진행료효평개。결과본연구납입병례102례，가평개병례96례，치료조환자적질병공제솔명현고우대조조，비교차이유통계학의의（ P＜0．05）；부치료조치료후혈청암배항원급세포각단백19편단항원수평현저강저，여치료전비교차이유통계학의의（P＜0．05）；량조소화도불량반응、골수억제방면차이무통계학의의（P＞0．05）。결론열료연합주제량다서자삼순단약화료료효교호，불량반응경，가작위노년폐암치료방안지일，동시감측폐암상관종류표지물동태변화이판단료효급예후。
Objective To evaluate clinical effect and safety of thermotherapy combined with weekly dose of docetaxel for elderly patients with non‐small cell lung cancer(NSCLC) .Methods A total of 102 elderly patients(≥65 years old) with NSCLC ,hospitalized in affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical Uni‐versity from January 2012 to January 2014 ,were enrolled in this study and divided into treatment group and control group ,51 patients in each group .The treatment group was treated by thermotherapy combined with weekly dose of docetaxel ,and the control group was treated by weekly dose of docetaxel .The clinical effects were evaluated and com‐pared after 2 weeks .Results A total of 96 patients were analyzed in 102 cases .The disease control rate of treatment group was obviously higher than that of the control group ,the difference was statistically significant (P<0 .05) .The levels of CEA and Cyfra19 of treatment group was decreased significantly ,compared with those before treating (P<0 .05) .There were no statisitical differences of the incidence of untoward alimentary tract reaction and myelosuppres‐sion between the two groups(P>0 .05) .Conclusion Thermotherapy combined with weekly dose of docetaxel is ef‐fective ,with only slight untoward reaction ,which could be a therapeutic regimen .Meanwhile ,monitoring dynamic fluctuation of lung cancer related tumor marker could evaluate the clinical effect and prognosis .